Logo

Gland Pharma Share Price

NSE: GLAND
|
Pharmaceuticals
₹ 2,462.30
+₹16.10 (0.66%)
1D
Last updated 03 Jul, 2026, 15:56 IST

Gland Pharma Share Price Today

As of 6 Jul 2026, Gland Pharma share price is ₹2,462.30. The stock opened at ₹2,469.00, compared to its previous close of ₹2,446.20. During today's trading session, Gland Pharma share price moved in the range of ₹2,445.20 to ₹2,524.60, with an average price of ₹2,484.90 for the day. Looking at its last 52-week, the stock has touched a low of ₹1,573.60 and a high of ₹2,528.30. On the performance front, Gland Pharma share price has increased by 43.51% over the last six months and is up 31.36% on a year-on-year basis.

₹2,445.20
0.66% up today
₹2,524.60
1D LOW
1D HIGH

Gland Pharma Returns Calculator

Open
₹2,469.00
High
₹2,524.60
Low
₹2,445.20
Prev. close
₹2,446.20
Circuit
L
H
₹1,969.90
₹2,954.70
52-week
L
H
₹1,573.60
₹2,528.30

Gland Pharma Shareholder Returns

Gland Pharma Share Price History

Mkt Cap Cr
40,340.90
P/E
39.27
P/B
3.89
ROE
9.92%
D/E
0.00
ROCE
14.02%
Div. Yield
0.82%
EPS(TTM)
78.88
Turnover
0.41
EV/EBITDA
19.56
Net Margin
0.00%
Op. Margin
0.00%
ROA
8.21%
Quick Ratio
0.00
Curr. Ratio
10.15
Based on fundamentals, this stock's
Step 5 of 5
Performance
Excellent
Gland Pharma outperforming all market indices
Step 1 of 5
Valuation
Overvalued
Gland Pharma appears overvalued compared to its peers
Step 5 of 5
Earnings
Excellent
Gland Pharma revenue, operating profit and net profit are growing
Peer Comparison
Peer comparison — key ratios
NameMkt Cap CrP/EP/BROED/EROCEBook ValueDiv. YieldTurnoverEPS(TTM)
Sun Pharmaceutical Industries4,49,048.0039.025.3713.74%0.6117.33%93.240.85%0.5610.90
Divis Laboratories1,77,179.0069.0010.5715.32%0.0019.56%629.490.45%0.5898.19
Torrent Pharmaceuticals1,57,804.0066.0317.0326.76%1.0518.30%16.900.90%0.4964.75
Cipla1,17,642.0025.472.8711.79%0.0015.66%2.891.06%0.4943.52
Dr. Reddy's Laboratories1,12,368.0027.032.9711.07%0.1812.54%375.780.59%0.6338.68
Zydus Lifesciences1,10,651.0021.604.0818.59%0.3117.35%235.250.09%0.3935.38
Lupin1,09,676.0020.484.8923.76%0.0424.88%659.050.75%0.61129.18
Mankind Pharma1,02,729.0053.006.3011.74%0.3413.13%397.020.04%0.5449.37
Aurobindo Pharma90,608.0025.872.399.25%0.1911.76%391.140.26%0.4841.58
Laurus Labs82,398.9060.2610.1018.21%0.4516.70%10.190.20%0.9713.72

Gland Pharma Financials

Full statement

Income Statement · Consolidated

Income Statement · Consolidated — all values in INR Crore
ParticularsMar 2025Mar 2024Mar 2023Mar 2022
Revenue₹5,616.50₹5,664.72₹3,624.60₹4,400.71
Other Income₹213.61₹170.24₹240.46₹223.94
Total Revenue₹5,830.11₹5,834.96₹3,865.06₹4,624.65
Total Expenses₹4,767.45₹4,702.42₹2,754.02₹3,006.09
Profit Before Tax₹1,062.66₹1,132.54₹1,054.58₹1,618.55
Tax₹364.13₹360.08₹273.54₹406.89
Profit After Tax₹698.53₹772.46₹781.04₹1,211.66
EPS - Basic₹42.40₹46.90₹47.44₹73.81
EPS - Diluted₹42.40₹46.89₹47.43₹73.64

Cash Flow · Consolidated

Cash Flow · Consolidated — all values in INR Crore
ParticularsMar 2025Mar 2024Mar 2023Mar 2022
Profit before tax₹1,062.66₹1,132.54₹1,054.58₹1,618.55
Income before WC changes₹1,274.60₹1,356.15₹1,092.77₹1,590.36
Change in Assets-₹141.92₹336.02-₹579.66-₹468.36
Change in Liabilities₹135.86-₹389.22₹161.72₹75.28
Change in WC-₹6.06-₹53.20-₹417.94-₹393.08
Cash flow from Operations₹914.73₹996.80₹363.97₹790.77
Cash flow from Investing₹1,704.74-₹1,756.91₹1,208.19-₹1,002.62
Cash flow from Financing-₹433.48-₹799.42₹14.92₹34.90
Total Cash Flow₹2,185.99-₹1,559.53₹1,587.08-₹176.95
Cash (Start of the year)₹357.09₹1,908.90₹318.82₹492.46
Cash (End of the year)₹2,556.21₹357.09₹1,908.90₹318.82

Balance Sheet · Consolidated

Balance Sheet · Consolidated — all values in INR Crore
ParticularsMar 2025Mar 2024Mar 2023Mar 2022
Non-Current Assets₹4,441.98₹5,016.09₹1,876.73₹1,981.54
Current Assets₹6,782.94₹5,645.15₹6,900.81₹5,852.08
Total Assets₹11,224.92₹10,661.25₹8,777.54₹7,833.62
Current Liabilities₹1,564.85₹1,398.36₹729.13₹582.03
Net Current Asset₹5,218.09₹4,246.79₹6,171.68₹5,270.05
Non-Current Liabilities₹509.33₹539.04₹89.68₹93.98
Equity Capital₹9,150.74₹8,723.84₹7,958.72₹7,157.62
Total Equity & Liabilities₹11,224.92₹10,661.25₹8,777.54₹7,833.62

Income Statement · Standalone

Income Statement · Standalone — all values in INR Crore
ParticularsMar 2025Mar 2024Mar 2023Mar 2022
Revenue₹4,116.15₹4,167.43₹3,616.53₹4,400.71
Other Income₹215.08₹166.67₹240.46₹223.94
Total Revenue₹4,331.22₹4,334.09₹3,856.99₹4,624.65
Total Expenses₹2,865.64₹2,928.60₹2,752.13₹3,005.61
Profit Before Tax₹1,465.59₹1,405.50₹1,048.40₹1,619.04
Tax₹375.83₹362.17₹272.58₹406.89
Profit After Tax₹1,089.75₹1,043.33₹775.83₹1,212.16
EPS - Basic₹66.15₹63.35₹47.12₹73.84
EPS - Diluted₹66.15₹63.33₹47.11₹73.67

Cash Flow · Standalone

Cash Flow · Standalone — all values in INR Crore
ParticularsMar 2025Mar 2024Mar 2023Mar 2022
Profit before tax₹1,465.59₹1,405.50₹1,048.40₹1,619.04
Income before WC changes₹1,460.43₹1,428.65₹1,085.78₹1,590.85
Change in Assets-₹121.33₹343.35-₹570.86-₹468.39
Change in Liabilities₹86.74-₹319.97₹163.86₹75.34
Change in WC-₹34.59₹23.38-₹407.00-₹393.05
Cash flow from Operations₹1,073.67₹1,135.97₹367.89₹791.29
Cash flow from Investing₹1,578.20-₹2,923.92₹1,208.22-₹1,010.23
Cash flow from Financing-₹339.54-₹7.40₹14.92₹34.90
Total Cash Flow₹2,312.33-₹1,795.35₹1,591.04-₹184.04
Cash (Start of the year)₹116.21₹1,905.22₹311.18₹491.92
Cash (End of the year)₹2,432.62₹116.21₹1,905.22₹311.18

Balance Sheet · Standalone

Balance Sheet · Standalone — all values in INR Crore
ParticularsMar 2025Mar 2024Mar 2023Mar 2022
Non-Current Assets₹4,654.66₹4,969.76₹1,884.84₹1,989.70
Current Assets₹5,766.96₹4,571.33₹6,888.34₹5,844.44
Total Assets₹10,421.62₹9,541.09₹8,773.18₹7,834.14
Current Liabilities₹523.77₹414.20₹730.20₹581.94
Net Current Asset₹5,243.20₹4,157.13₹6,158.14₹5,262.50
Non-Current Liabilities₹142.75₹131.60₹89.68₹93.98
Equity Capital₹9,755.10₹8,995.29₹7,953.30₹7,158.23
Total Equity & Liabilities₹10,421.62₹9,541.09₹8,773.18₹7,834.14
* All values are in INR Crore
Qty
Bid
0
0
0
0
0
0
0
0
0
0
Ask
Qty
2462.3
351
0
0
0
0
0
0
0
0
Bid Total: 0
Ask Total: 351
Buy orders: 0%
Sell orders: 100%
Bearish
3
Neutral
4
Bullish
1
Slightly Bearish
by SEBI experts
Expert Pick
EXPPICK
Stop-loss
Entry price
Target
Indicator
Value
Verdict
RSI (14)
68.37
Neutral
ATR (14)
77.76
Neutral
STOCH(9,6)
81.06
Bearish
STOCH RSI (14)
76.87
Neutral
ADX(9)
47.89
Bearish
UO(9)
50.97
Neutral
ROC(12)
13.02
Bullish
WillR(14)
-18.31
Bearish
Period
Simple value
Exponential vaue
5D
2448.34
2432.65
10D
2356.66
2382.12
20D
2300.2
2316.99
50D
2128.75
2165.08
100D
1939.11
2027.58

About Gland Pharma

Gland Pharma logo
ISIN
INE068V01023
Sector Market Cap
₹ 40,340.9 Cr

Gland Pharma Limited is an India-based generic injectables manufacturer. The Company specializes in sterile injectables, oncology, and ophthalmic, with a specific focus on complex injectables, New Chemical Entities (NCE)-1s, First-to-File products, and 505(b)(2) filings. The Company manufactures a range of dosage formulations, including solutions, suspensions, and lyophilized products. Its product portfolio includes delivery methods such as pre-filled syringes, vials, ampoules, bags, and dry powder injections. It also produces generic injectables in liquid, lyophilized, suspension, and pre-filled syringe forms. Its molecules include Enoxaparin Sodium, Cisplatin, Lacosamide, Rocuronium Bromide, Zoledronic Acid, Vancomycin, and others. Its therapeutic products categories include Anti Malarials, Anti-Infectives, Anti-Neoplastics, Gynecological, Hormones, and others. The Company functions primarily on a business-to-business model. Its subsidiary is Gland Pharma International Pte. Ltd.

Gland Pharma Financial Highlights

  • Revenue: Gland Pharma reported revenue of ₹6,746.98 crore in FY26 vs ₹5,830.11 crore in FY25. It showed an increase of 15.73% on a yearly basis.
  • Operating Profit: Gland Pharma reported an operating profit of ₹1,464.58 crore in FY26 vs ₹1,062.66 crore in FY25. It showed an increase of 37.82% on a year-on-year basis.
  • Net Profit: Gland Pharma reported a net profit of ₹1,027.32 crore in FY26 vs ₹698.53 crore in FY25. It showed an increase of 47.07% on a yearly basis.

Gland Pharma Quarterly Result Highlights

  • Gland Pharma reported revenue of ₹1,854.26 crore in Mar 2026, compared with ₹1,758.53 crore in Dec 2025, representing an increase of 5.44% on a quarter-on-quarter (QoQ) basis.
  • Gland Pharma reported an operating profit of ₹505.80 crore in Mar 2026, compared with ₹362.13 crore in Dec 2025, representing an increase of 39.67% on a quarter-on-quarter (QoQ) basis.
  • Gland Pharma reported a profit of ₹366.68 crore in Mar 2026, compared with ₹261.48 crore in Dec 2025, reflecting an increase of 40.23% on a QoQ basis.
  • The earnings per share (EPS) of Gland Pharma stood at ₹42.40 during Mar 2026.
Know more
Promoters
51.83%
FII
7.30%
Other DII
1.58%
Retail and other
7.52%
Mutual funds
31.78%
Foreign institutions - FII
Compare against other stocks
Gland Pharma logo
Gland Pharma
Pharmaceuticals
Add Stock
Add Another

FAQs on Gland Pharma Share Price